Nearly three decades after its failed bid for FDA approval, the cardiovascular drug levosimendan is still struggling to ...
Scholar Rock has shed Novo Nordisk’s troubled Catalent facility as a contract manufacturer in its FDA refiling for apitegromab, a candidate for spinal muscular atrophy. The Cambridge, ...
Bristol Myers Squibb has laid out plans for a $2.3 billion manufacturing facility in Houston, set for completion in 2030. The plant will cover 600,000 square feet and employ nearly 500 people.
The FDA has denied ITM Isotopes Technologies’ lead pipeline candidate for a rare group of tumors due to qualms over the drug’s manufacturing. The FDA’s complete response letter did not raise any ...
Abbott has enlisted telenovela star Gabriela Spanic to push the message that getting screened for colon cancer doesn’t have ...
Injected weight loss drugs remain favored over newer oral treatments by a significant margin, with Eli Lilly’s Zepbound leading the pack, according to a survey of healthcare specialists by Spherix ...
Two and a half years into his tenure as Emergent BioSolutions CEO, Joseph Papa is executing another round of restructuring to ...
It’s been years since Big Pharma last witnessed a megamerger. In the late 2010s, Takeda bought Shire, AbbVie acquired ...
Despite a major curveball thrown by the FDA earlier this year, Moderna has managed to strike true with a U.S. approval for its mRNA-based influenza vaccine. | Despite a major curveball thrown by the ...
Personalized AI health app VerilyMe is visualizing expanded eye health education in a new partnership with eye health-focused drugmaker Bausch + Lomb. | The partnership marks Basuch + Lomb's foray ...
Galderma Laboratories has landed a blow on Sanofi in its multi-case advertising row, driving the French drugmaker to change ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results